Antibodies that bind myostatin, compositions and methods

Disclosed is an isolated myostatin-specific antibody comprising at least one light chain and at least one heavy chain, wherein the light chain comprises a constant region and a variable region that comprises three complementarity determining regions (CDRs) and the heavy chain comprises a constant re...

Full description

Saved in:
Bibliographic Details
Main Authors HAN HQ, ZHOU XIAOLAN, LU HSIENG SEN, ARORA TARUNA, CHEN QING
Format Patent
LanguageEnglish
Published 27.02.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Disclosed is an isolated myostatin-specific antibody comprising at least one light chain and at least one heavy chain, wherein the light chain comprises a constant region and a variable region that comprises three complementarity determining regions (CDRs) and the heavy chain comprises a constant region and a variable region that comprises three CDRs, wherein the light chain CDR1, CDR2 and CDR3 are KASQDINKYVA, YTSWLQP and LQYDNLLYT, respectively, and the heavy chain CDR1, CDR2 and CDR3 are RYWMN, XIRLKSDNYATHYAESVKG and GLDY, respectively. Also disclosed is the use of the above-described myostatin-specific antibody in the preparation of a medicament for treatment or prevention of a disease or condition associated with activity of myostatin.
AbstractList Disclosed is an isolated myostatin-specific antibody comprising at least one light chain and at least one heavy chain, wherein the light chain comprises a constant region and a variable region that comprises three complementarity determining regions (CDRs) and the heavy chain comprises a constant region and a variable region that comprises three CDRs, wherein the light chain CDR1, CDR2 and CDR3 are KASQDINKYVA, YTSWLQP and LQYDNLLYT, respectively, and the heavy chain CDR1, CDR2 and CDR3 are RYWMN, XIRLKSDNYATHYAESVKG and GLDY, respectively. Also disclosed is the use of the above-described myostatin-specific antibody in the preparation of a medicament for treatment or prevention of a disease or condition associated with activity of myostatin.
Author HAN HQ
ARORA TARUNA
ZHOU XIAOLAN
LU HSIENG SEN
CHEN QING
Author_xml – fullname: HAN HQ
– fullname: ZHOU XIAOLAN
– fullname: LU HSIENG SEN
– fullname: ARORA TARUNA
– fullname: CHEN QING
BookMark eNrjYmDJy89L5WSwcMwryUzKT8lMLVYoyUgsUUjKzEtRyK3MLy5JLMnM01FIzs8tyC_OLMnMzytWSATJpZZk5KcU8zCwpiXmFKfyQmluBjk31xBnD93Ugvz41OKCxOTUvNSSeL8oMwMLIwMzR2OCCgAaiS9D
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID NZ608206A
GroupedDBID EVB
ID FETCH-epo_espacenet_NZ608206A3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:47:45 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_NZ608206A3
Notes Application Number: NZ20110608206
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150227&DB=EPODOC&CC=NZ&NR=608206A
ParticipantIDs epo_espacenet_NZ608206A
PublicationCentury 2000
PublicationDate 20150227
PublicationDateYYYYMMDD 2015-02-27
PublicationDate_xml – month: 02
  year: 2015
  text: 20150227
  day: 27
PublicationDecade 2010
PublicationYear 2015
RelatedCompanies AMGEN INC
RelatedCompanies_xml – name: AMGEN INC
Score 2.9797826
Snippet Disclosed is an isolated myostatin-specific antibody comprising at least one light chain and at least one heavy chain, wherein the light chain comprises a...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Antibodies that bind myostatin, compositions and methods
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150227&DB=EPODOC&locale=&CC=NZ&NR=608206A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LSwMxEB5qFfWm9f0oOcieXNRss4_DIu0-KEK3RaqUXkqyZnUPZosbEf-9Sdiql95CAsNkYF7JfDMAV3dBQHNCXRsHnNg9Zf9syplnc8_hXFnEwicaOzzK3OFT72FGZi14XWFhTJ_QL9McUWlUrvRdGnu9_HvEik1tZX3DSrVV3afTMLaa7FhFNxh7VjwIk8k4HkdWFIXZ3MoeQ1e7Ore_AZs6htZN9pPngYakLP_7k3QPtiaKlJD70OKiAzvRauxaB7ZHzW-3WjaKVx-A3xeyZJUu-UPyjUqkEtoX9P5daUBQKa6RLg1f1V8hqs_MaOj6ELppMo2GtmJh8XvZRTZvWHWOoC0qwU8AFQSznBfcw4UOX5ygwLkf3DKHUZdhkp_C8RoiZ2tPzmFXy8ugs70LaMuPT36p_KtkXSObH_5Ogas
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV07T8MwED6VgigblPejZECZiACneQ0RapNGAZq0QgFVXaI4OJABpyJGiH-PbaXA0s2ypdP5pHvZ990BXNw4TpYbmakhhxhan9s_LSPY0oilE8ItYmEbAjscxWb41L-fGbMWvC6xMLJP6Jdsjsg1Kuf6zqS9Xvw9YvmytrK-wiXfqm6DxPXVJjvm0Q1CluoP3dF04k881fPceK7Gj64pXJ05WIN1S7TmFXHT81BAUhb__UmwDRtTToqyHWgR2oWOtxy71oXNqPnt5stG8epdsAeUlbgSJX8Ke8uYwhPaF-X9uxKAoJJeKqI0fFl_pWTiTI6GrvegF4wSL9Q4C-nvZdN43rCq70ObVpQcglIYCOekIBYqRPiiOwXKbeca6zgzMTLyIzhYQeR45ck5dMIkGqfju_jhBLaE7CRS2zqFNvv4JGfc1zLck3L6ATcAhJg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Antibodies+that+bind+myostatin%2C+compositions+and+methods&rft.inventor=HAN+HQ&rft.inventor=ZHOU+XIAOLAN&rft.inventor=LU+HSIENG+SEN&rft.inventor=ARORA+TARUNA&rft.inventor=CHEN+QING&rft.date=2015-02-27&rft.externalDBID=A&rft.externalDocID=NZ608206A